On Schwab they show that the price of RMTI is down 11.21% for 1 year while the S&P US Health Care is up 21.60%. This really shows how successful the shorts have been look at what RMTI has accomplished in the past year. An offering was completed. The sales of distillate to DaVita and other dialysis clinics has increased. Calitriol was approved while shorts claimed it would never happen . The Baxter distribution deal was signed Triferic ADCOM was 8ye/3no after the shorts said it wouldn't happen. AF wrote that the ADCOM vote was wrong and Triferic would not be approved. The FDA approved Triferic. The shorts have been consistently wrong. RMTI's share price should be much higher when you look at the health care sector for the last year and at the analyst target prices.
RMTI implied they would not need to do an offering, then they did an offering to many investors surprise which lowered the stock price. RMTI has an abundance of cash now, so much so that they paid off all their loans and still have enough cash on hand to successfully launch both Calitriol & Triferic This stock should be much higher however shorts have been very devious at scaring buyers away with statements like this one which has no basis in facts or logic. IMHO shorts are in a bad place when they have to come up with inane statements.like this one.
They were hoping to prove that they got significant increase in ESA. The data showed very slight increase, not statistically significant. Therefore the most they could report was maintenance. If they could have demonstrated significant increase that would have been icing on the cake. Keep in mind they still got the cake. What shorts are missing is this non toxic iron is easily delivered during dialysis. There is this ease of delivery and the more non toxic iron, safe iron, you you can give patient verses iron with side effects the better the health of the patient. They met their primary objective and it is approved by the FDA. RMTI has the approval, the ability to competitively price Triferric, the network & because of the recent offering the $ money to successfully launch not only Triferic but also Calitriol.
I completely disagree with your reasoning. The scientific method requires you eliminate all variables except the one you are trying to study. Triferic increases iron in dialysis patients without toxic build up of iron in the liver or other cells in the body. This was demonstrated in the study and Triferic has now been approved by the FDA. If a patient iron levels are not met 100% by using Triferic an alternate source of iron can be used to supplement Triferic but negates the absolute proof you are looking for in the study and the patient is removed from the study.. RMTI had enough patients complete the study to prove their premiss. Shorts have pointed out the low but increasing profit margin as a reason to short the stock. But by signing contracts with low profit margins with Da Vita and other dialysis companies RMTI has built up a network that will enable them to easily launch sales of Calitriol and Triferic. There already has been discussion that the demand for Calitriol may exceed the supply. Triferic does not not cause iron build up in the liver. This is the game changer which will enable Triferic launch to be successful compared to other poor launches of iron treatment. At the present time you are making money-congratulations. Eventually the tide will turn in favor of the longs.
Reminder most analyst have a price target in the mid $20's. Now the shorts are telling us to book our profits and to sell on the good news. Selling too quickly will allow them to cover for very little. Over 7million shares are shorted since there are so many shorts that follow Adam F's advice. This company has tremendous potential. I'm not selling for a while hoping for a higher pps.
It looks like some shorts are starting to cover.
Sentiment: Strong Buy
We have had only good news during January. we even had Oppenheimer join the list of analyst rating RMTI as outperform with a price target in the mid $20s.. The price 10 days ago was $11.81 with very little being said on the board by the shorts, 8 days ago the price closed at $11.92. Since then there has been no negative news, it is a waiting game to hear the FDA decision. The shorts have taken this quite time to effectively create doubt and drive the price of the stock down. Keep your focus on the facts/data . The data has not changed! The waiting game is nearly over. In my opinion more good news is coming soon.
Sentiment: Strong Buy
I added today, We are so close to a definitive answer. I look at the data which in my opinion favors approval. I look at all the post by the shorts and they do not emphasize the data. You always wonder why so many shares shorted. Why did the price drop yesterday? Do the shorts know something I do not know? I purchased most of my shares at a lower price however I am going with the data and adding even more at this price. I have followed this stock for over a decade. I believe Triferric will be approved. Looking at the data not the hype is what I'm doing. We will know soon if it is the right decision.
You indicated you were not going to post again until the decision was reached. You just made a blanket statement with no facts to back it up. Why not say you have a snowball stored in hell and we will see it next Friday?
Good statement this time. Apparently Oppenheimer"s view does not agree with your perspective since they initiated coverage at outperform.
The last time it hit $15 there was no approval of Triferric by the FDA. Approval should take us higher than $15. They say you do not lose money taking a profit. I will hold for a little higher price to take a profit. Also I will sell some in increments just as I bought in increments. I too am retired and enjoy reading your thoughts. Best of luck !
Summer Street still has RMTI listed as a buy, Why? Take time to see how many analyst list RMTI as a buy , outperform, & market outperform. How many agree with AF? The odds still are not in your favor!
I just bought again on this dip. We are close to the definitive answer. RMTI is now my largest holding in my portfolio. There are so many reasons to buy. ADCOM 8+,3-. for Triferric , Calotriol, $ on hand, Good management team, Baxter, good contracts. If you follow this board you know this and more. Waiting for the decision on or before January 24, 2915
8+, 3-, is better than 2 to 1 odds. I'm betting on approval and no CRL. I have followed this stock for over a decade. RMTI is in a stronger place than when it was above $15 a share years ago. I added more shares today we are less than three weeks away from the FDA decision for Triferric. The company was recently successful with Calitriol, We will have a definitive answer soon.